New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2013
16:04 EDTARRYArray BioPharma to initiate Phase 3 trial evaluating MEK162
Array BioPharma announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer during the summer of 2013. The study, called MILO, will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy treatments and is designed for worldwide regulatory submissions, including with the U.S. Food and Drug Administration and the European Medicines Agency. Array invented MEK162 and licensed worldwide rights to develop and commercialize the drug to Novartis in April 2010. The MILO study follows a recent announcement by Novartis detailing plans to initiate Phase 3 trials of MEK162 in both NRAS- and BRAF-mutant melanoma and will be covered as part of the Novartis/Array co-development agreement under which costs are capped annually and in total for Array.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
10:11 EDTARRYHigh option volume stocks
Subscribe for More Information
September 28, 2015
12:25 EDTARRYArray data have positive read-through to Phase 3 trial, says Piper Jaffray
Subscribe for More Information
12:22 EDTARRYArray says binimetinib-encorafenib combo shows differentiated tolerability
Subscribe for More Information
September 25, 2015
08:39 EDTARRYArray BioPharma to host conference call
Conference call to discuss preliminary results from two melanoma trials and a colorectal cancer trial will be held on September 28 at 9 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use